BioNTech, Pfizer’s COVID-19 vaccine shows positive results in early stage human trial
A COVID-19 vaccine developed by German biotech firm BioNTech and the US pharmaceutical major Pfizer was found to be well tolerated in early-stage human trials, the companies said on Wednesday. Testing of two dosages of
A COVID-19 vaccine developed by German biotech firm BioNTech and the US pharmaceutical major Pfizer was found to be well tolerated in early-stage human trials, the companies said on Wednesday. Testing of two dosages of BNT162b1 drug on 24 healthy volunteers showed that after 28 days, they had developed higher levels of COVID-19 antibodies than typically seen in infected people.
